Trade Policy

An India-EU trade deal sets ground for a free trade agreement to lower tariffs on pharma, though an investment protection agreement – likely influencing data exclusivity – will be concluded later. Will the US now reconsider its India tariffs?

Two major EU trade agreements are on hold, with ramifications for the pharmaceutical market.

The announced deal means that of 17 companies the White House notified in July, only AbbVie and Regeneron have not yet made a deal.

Experts at a recent summit discussed the complexities and impact of US MFN pricing from a payer perspective and emphasized the importance of a centralized purchaser of drugs to effectively negotiate prices. The potential rise of 'confidential discounts' in Germany was another key talking point.

The trade body, Medicines Australia, has flagged a downturn in new drug launches, attributing it to the effects of President Trump’s trade policies. It has called for “urgent action.”

India has cut GST on active ingredients in drugs like Novartis’s Zolgensma, J&J’s Darzalex and Roche’s Ocrevus. But Trump added a H1B visa brick to his trade wall while US Secretary of State Marco Rubio hinted at a relook at a punitive Russian oil tariff. Scrip considers the impact

As US Secretary of State Marco Rubio hints at reconsideration of a punitive Russian oil tariff, Trump adds an H-1B visa brick to his trade wall and India lowers GST on cancer and rare disease drugs, the Pink Sheet considers the impact.

An executive order has given the go-ahead for US tariffs on Japan to be amended to “zero percent” for generics, just weeks after the EU revealed an effective exemption from its own US tariffs. Meanwhile, a separate order suggests that generics could enjoy broader global exemptions from tariffs.

The US International Trade Commission has banned smart rings from Ultrahuman and RingConn after Oura Health's patent infringement case. Ultrahuman countersued, claiming Oura infringes its intellectual property. Sales and marketing of the affected rings will cease on October 22.

As US-India ties rupture, what could it mean for joint calls by the two nations to de-risk the pharma supply chain and could New Delhi consider non-tariff tools to make a point?

Centrient CEO Rex Clements talks about how the industry landscape is shifting for the European pure-play antibiotics producer, addressing issues including supply-chain security, US tariffs, localized manufacturing and AMR, as well as explaining how the firm is incorporating AI into its plans.

The European generics industry has welcomed news that generic medicines will be exempt from tariffs under the latest EU-US trade agreement.